Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | LPL | P06858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988520 | 0.86 | LIPG (0.40) | AKR1B1CXCR2LIPGLPLTDP1 | |
| SCHEMBL29179974 | 0.86 | CXCR2 (0.40) | CXCR2LIPGLPLP4HBROCK1 | |
| SCHEMBL17389030 | 0.85 | LIPG (0.39) | AKR1B1CXCR2LIPGLPLTDP1 | |
| SCHEMBL902458 | 0.84 | LIPG (0.49) | CXCR2LIPGLPLTDP1P4HB | |
| SCHEMBL3319492 | 0.83 | CXCR2 (0.41) | CXCR2LIPGLPLP4HBROCK1 | |
| SCHEMBL29973532 | 0.83 | KDM4E (0.42) | CXCR2LIPGLPLP4HBROCK1 | |
| SCHEMBL14656987 | 0.83 | KDM4E (0.42) | CXCR2LIPGLPLP4HBROCK1 | |
| SCHEMBL13202078 | 0.81 | LPL (0.43) | CXCR2LIPGLPLP4HBROCK1 | |
| SCHEMBL11105 | 0.81 | PKM (0.44) | CXCR2 | |
| SCHEMBL29107963 | 0.81 | CYSLTR2 (0.44) | CXCR2LIPGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976608-B1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3976608-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243459-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243459-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | CELLUMEN INC. | 2009-08-20 | — | — | US | disclosed |
| EP-2024371-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007134434-A1 | PHENANTHRENE DERIVATIVES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209571-A1 | Phenanthrene derivatives as MPGES-1 inhibitors | PTGES, PTGS1, PTGES2 | AKR1B1 350/4885CXCR2 770/4885LIPG 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.